Pharmabiz1d
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
The Pharma Letter3d
Boehringer’s nerandomilast meets endpoint in Phase III study
Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...
Boehringer Ingelheim Limited: Boehringer's nerandomilast meets primary endpoint in Phase III study FIBRONEER-ILD, in progressive pulmonary fibrosis
Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Illustrative photo Boehringer Ingelheim Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast ...
Hosted on MSN4d
5 Delicious Cocktail Recipes for the Ultimate Galentine's Day Celebration
The true essence of Galentine's Day is all about bringing your besties together for a day filled with endless laughter, deep ...
Moneylife27d
Shakeout in Small Caps. What Next?
Last week, the CNX SmallCap 100 index cracked by 7.3%. On Monday, it crashed a further 4%. The last time the index fell more than this was way back in December 2022 (8.33%). This serious decline comes ...
Forbes29d
Using AI And ML To Transform Care Delivery Processes
But do these positive changes reflect on the quality of care, and do patients benefit from AI and ML-powered solutions? In this article, I share my take on the transformative potential of AI and ...